Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230221 | 1.00 | PARP1 (0.62) | PARP1PARP2KDRCHEK1CDK4 | |
| SCHEMBL29406940 | 1.00 | PARP1 (0.62) | PARP1PARP2KDRCHEK1CDK4 | |
| SCHEMBL12845989 | 0.87 | PARP1 (0.58) | PARP1PARP2CHEK1 | |
| SCHEMBL12846158 | 0.87 | PARP1 (0.58) | PARP1PARP2CHEK1 | |
| SCHEMBL12846276 | 0.87 | PARP1 (0.55) | PARP1PARP2 | |
| SCHEMBL7705318 | 0.85 | PARP1 (0.59) | PARP1PARP2ABCG2 | |
| SCHEMBL12845917 | 0.84 | PARP1 (0.54) | PARP1PARP2KDR | |
| SCHEMBL12846159 | 0.83 | PARP1 (0.54) | PARP1PARP2 | |
| SCHEMBL14169516 | 0.83 | PARP1 (0.71) | PARP1PARP2ABCG2 | |
| SCHEMBL12845916 | 0.83 | PARP1 (0.56) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | claimed |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | claimed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | claimed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | claimed |
| EP-2086525-B1 | METHOD OF RADIO-SENSITIZING TUMORS USING A RADIO-SENSITIZING AGENT | CEPHALON INC (US) | 2010-10-06 | — | — | EP | claimed |
| EP-2086525-A1 | METHOD OF RADIO-SENSITIZING TUMORS USING A RADIO-SENSITIZING AGENT | Cephalon, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080146556-A1 | Method of radio-sensitizing tumors using a radio-sensitizing agent | CEPHALON, INC. (US) | 2008-06-19 | — | — | US | claimed |
| WO-2008063644-A1 | METHOD OF RADIO-SENSITIZING TUMORS USING A RADIO-SENSITIZING AGENT | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-17 | — | — | US | disclosed |
| EP-1754707-B1 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080146556-A1 | Method of radio-sensitizing tumors using a radio-sensitizing agent | CEPHALON, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146556-A1 | Method of radio-sensitizing tumors using a radio-sensitizing agent | CEPHALON, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146556-A1 | Method of radio-sensitizing tumors using a radio-sensitizing agent | CEPHALON, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008063644-A1 | METHOD OF RADIO-SENSITIZING TUMORS USING A RADIO-SENSITIZING AGENT | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063644-A1 | METHOD OF RADIO-SENSITIZING TUMORS USING A RADIO-SENSITIZING AGENT | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885KDR 2782/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885KDR 2782/4885 |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885KDR 1782/4885 |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885KDR 1782/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885PARP2 108/4885KDR 1268/4885 |
| US-20080146556-A1 | Method of radio-sensitizing tumors using a radio-sensitizing agent | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885KDR 1623/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | PARP1 248/4885PARP2 196/4885KDR 2367/4885 |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885KDR 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.